RadNet, Inc. (RDNT) stock
RDNTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3056% above fair value
$76.42+0.38 (+0.50%)
Close on Nov 13, 2026Market cap $6.01BP/E –Yield –
RadNet r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for RadNet
RadNet has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?